Nexentis Technologies (NXTS) Net Shares Issued and Repurchased (2018 - 2025)
Nexentis Technologies (NXTS) posted Net Shares Issued and Repurchased of $37.0 for Q4 2025, down 97.14% on a QoQ basis from $1294.0 in Q1 2025, and down 87.06% year-over-year from $286.0 in Q4 2024.
Analysis
Nexentis Technologies (NXTS) Net Shares Issued and Repurchased (2018 - 2025) Analysis & Trends
Nexentis Technologies has reported Net Shares Issued and Repurchased for 8 years, with the latest figure at $37.0 in Q4 2025.
- On a quarterly basis, Net Shares Issued and Repurchased fell 87.06% year-over-year to $37.0 in Q4 2025; TTM through Dec 2025 was $37.0, a 87.06% decrease from a year earlier, with the FY2025 full-year figure at $37.0, down 87.06% from the prior year.
- Net Shares Issued and Repurchased was $37.0 for Q4 2025 at Nexentis Technologies, down from $1294.0 in the prior quarter.
- The five-year high for Net Shares Issued and Repurchased was $11905.0 in Q4 2021, with the low at $37.0 in Q4 2025.
- Average Net Shares Issued and Repurchased over 5 years is $4258.7, with a median of $3654.5 recorded in 2022.
- The sharpest annual moves came in 2023 and 2024: Net Shares Issued and Repurchased changed 0.0% in 2023, then tumbled 95.25% in 2024.
- Over 5 years, Net Shares Issued and Repurchased stood at $11905.0 in 2021, then slumped by 49.48% to $6015.0 in 2022, then changed by 0.0% to $6015.0 in 2023, then sank by 95.25% to $286.0 in 2024, then sank by 87.06% to $37.0 in 2025.
- The last three Net Shares Issued and Repurchased figures came in at $37.0 (Q4 2025), $1294.0 (Q1 2025), and $286.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.94 Bn | 195.95 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.74 Bn | 176.57 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.05 Bn | 124.20 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.43 Bn | 74.44 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.23 Bn | 56.04 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.42 Bn | 48.28 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.77 Bn | 30.47 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.62 Bn | 30.33 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Nexentis Technologies | 1.38 Mn | -7.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 37.00 |
| Mar 31, 2025 | 1,294.00 |
| Dec 31, 2024 | 286.00 |
| Dec 31, 2023 | 6,015.00 |
| Dec 31, 2022 | 6,015.00 |
| Dec 31, 2021 | 11,905.00 |
| Dec 31, 2020 | 92,574.00 |
| Mar 31, 2020 | 58,333.00 |
| Dec 31, 2019 | 109,526.00 |
| Dec 31, 2018 | 416,669.00 |